

BIOSPECIFICS TECHNOLOGIES CORP  
Form 8-A12B  
January 06, 2009

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES  
PURSUANT TO SECTION 12(b) OR (g) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): January 6, 2009

**BIOSPECIFICS TECHNOLOGIES CORP.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or incorporation or organization)

**11-3054851**

(I.R.S. Employer Identification No.)

**35 Wilbur Street, Lynbrook, New York**

(Address of principal executive offices)

**11563**

(Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

Title of each class  
To be so registered:

Name of each exchange on which  
each class is to be registered:

**Common Stock**

**The Nasdaq Stock Market LLC**

If this Form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), please check the following box.

Q

If this Form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), please check the following box.

..

Securities Act registration statement file number to which this form relates: \_\_\_\_\_ (if applicable)

Securities to be registered pursuant to Section 12(g) of the Act: **None**

---

Introductory Comment

Throughout this Current Report on Form 8-K, the terms "we," "us," "our" and "Company" refer to BioSpecifics Technologies Corp.

ITEM 1. DESCRIPTION OF REGISTRANT'S SECURITIES TO BE REGISTERED

The capital stock to be registered hereby consists of shares of the Company's common stock, par value \$0.001 per share (the "Common Stock"). Each share of our Common Stock entitles the holder thereof to one vote on each matter submitted to a vote of the stockholders of the Company. Subject to dividend preferences that may apply to any outstanding shares of our preferred stock, holders of our Common Stock will receive ratably any dividends our board of directors declares out of funds legally available for that purpose. In the event that the Company liquidates, dissolves or winds up its affairs, the holders of our Common Stock are entitled to share ratably in all assets remaining after payment of debts and other liabilities and any preferential amounts to which the holders of any outstanding shares of preferred stock shall be entitled to receive upon dissolution, liquidation, or winding up. Our Common Stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.

ITEM 2. EXHIBITS

Pursuant to the instructions as to exhibits, no exhibits are required to be filed herewith.

---

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

Date: January 6, 2009

BIOSPECIFICS TECHNOLOGIES CORP.  
(Registrant)

/s/ Thomas L. Wegman  
Thomas L. Wegman  
President

---